For citations:
Ganshina I.P., Artamonova E.V., Zhulikov Y.A., Koroleva M.V., Zhukova L.G., Filonenko D.A., Sukhova M.V., Anokhina E.P., Aseeva I.G., Averyanova S.V., Bolshakova S.A., Vysotskaya V.V., Vasiliev A.E., Volkonsky M.V., Voronin D.V., Valkin D.L., Goldberg V.E., Dudnikova E.A., Dashyan G.A., Zharkova O.V., Zukov R.A., Ivanov A.M., Kiseleva E.E., Kostalanova Yu.V., Kaganov O.I., Lazareva D.G., Lyubimova O.A., Myslevtsev I.V., Mikhalyuk V.V., Mezhidova H.M., Mukhitova M.R., Menshikov K.V., Orlov A.E., Orlova S.A., Popova N.O., Peganova E.V., Pecheny A.P., Rats N.M., Simolina E.I., Sultanbaev A.V., Stepura Yu.E., Sukhova M.V., Temirsultanova T.H., Usoltseva I.S., Shirokova O.N., Shatalova V.A., Shaidorov M.V. Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice. Medical alphabet. 2025;(11):17-24. (In Russ.) https://doi.org/10.33667/2078-5631-2025-11-17-24
Email this article 